Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAarif AhsanCMChristine MantisCRCesar Rodriguez

Discussion

Loading...

Member takes

Overview

Correlative biomarker analyses reveal that etentamig treatment elevates T-cell activation and proinflammatory cytokine responses in RRMM patients, suggesting therapeutic potential.

Key Points

  • Rapid and transient proinflammatory cytokines observed in RRMM patients receiving etentamig treatment, promoting T-cell activity.
  • Cytokine release syndrome occurrence correlated with elevated IL-6 and tumor necrosis factor–a levels during treatment.
  • Open-label analyses of Phase 1 trials focused on T-cell activation and exhaustion in patients treated with varying doses of etentamig.
  • The effectiveness of etentamig is independent of baseline soluble BCMA levels, indicating substantial therapeutic promise in MM.

Cite This Study

Ahsan et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7c8https://doi.org/10.1182/blood-2025-2204
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis2025 · 3 citations
  2. 2Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study2025 · 2 citations
  3. 3Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma2025
  4. 4Restarting etentamig therapy after dosing delays or interruptions: Population pharmacokinetics (PopPK) and PK/PD simulations and supporting clinical data2025
  5. 5Teclisito: Low-intensity teclistamab in the outpatient setting for Relapsed/Refractory multiple myeloma2025